Drug Trial Radar · NCT04336124
Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
Last checked: Nov 19, 2026Latest source record: Nov 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
May 25, 2020
Primary completion
Feb 8, 2021
Study completion Apr 8, 2022
Sponsor
- Lead sponsor
- TaiRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CVM-1118 Immediate-release (IR) Capsule and CVM-1118 Extended-release (ER) Capsule are proprietary oncology products developed by TaiRx, Inc. for the treatment of patients suffering from advanced cancer. Due to the short elimination half-life of CVM-1118 IR capsules, the extended release (ER) formulation, containing mini-tablets in hard capsule, has been developed to prolong the drug absorption and longer exposure after oral administration. The designed dose of CVM-1118 ER was 200 mg per capsule to provide a more patient-compliant and safe dosage of CVM-1118. The clinical study CVMEX-001 is therefore designed to evaluate the safety and pharmacokinetics of CVM-1118 extend release (ER) Capsule (200 mg/capsule) in patients with advanced cancer.
Conditions
- Advanced Cancer
Interventions
CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)Drug
Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles. Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing. A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day. If 2 or more patients experience a DLT, no further dose escalation will occur.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT) of CVM-1118 ER CapsuleTime frame: up to 28 days
- Maximum tolerated dose (MTD) of CVM-1118 ER CapsuleTime frame: up to 28 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
China Medical University Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.